Pyxis Oncology Appoints Experienced Biotech Executive Tom Civik as Interim CEO Following Dr. Sullivan's Departure

summarizeSummary

Pyxis Oncology announced the departure of CEO Dr. Lara Sullivan and appointed current director Tom Civik, an experienced biotech executive, as Interim CEO to guide strategic focus and program continuity.

check_boxKey Events

• CEO Departure

  Dr. Lara Sullivan, M.D. ceased serving as Chief Executive Officer and principal executive officer, effective February 2, 2026.

• Interim CEO Appointment

  Tom Civik, a current director with a strong track record in oncology development and M&A, was appointed Interim Chief Executive Officer and principal executive officer, effective February 2, 2026.

• Strategic Mandate

  The leadership transition is intended to support strategic focus and program continuity, particularly for the company's lead program, MICVO.

• Performance-Based Compensation

  Mr. Civik's compensation includes an annualized base salary of $710,000, a target bonus, and stock option grants representing 1.5% of outstanding shares, with a portion contingent on a successful financing or strategic transaction.

auto_awesomeAnalysis

Pyxis Oncology announced a significant leadership transition with the departure of Dr. Lara Sullivan, M.D. as CEO and the immediate appointment of Tom Civik as Interim CEO. Mr. Civik, a current director, brings a strong background in oncology development and commercialization, notably leading Five Prime Therapeutics through its $1.9 billion acquisition by Amgen. This change, framed as supporting strategic focus and program continuity, is critical for a clinical-stage biopharmaceutical company. The compensation package for Mr. Civik includes substantial equity grants (totaling 1.5% of outstanding shares), with a portion vesting upon a successful financing or strategic transaction, indicating a clear mandate for value creation.